Powerful Medical Announces Breakthrough Device Designation for PMcardio STEMI AI ECG Model

Powerful Medical, a leading company in AI-powered cardiovascular diagnostics, has received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its PMcardio STEMI AI ECG model. This recognition highlights the model’s potential to improve the early detection of ST-elevation myocardial infarction (STEMI) and STEMI equivalents – critical heart conditions that require urgent medical attention.

The PMcardio system stands out as the only tool capable of identifying both STEMI and STEMI equivalents through ECG. This aligns with the growing shift towards recognising Occlusion Myocardial Infarction (OMI) and meets a significant need for more accurate and timely diagnosis.

This is particularly important in healthcare settings where immediate specialist support is not available. Many patients in rural or smaller centres do not reach catheterisation labs in time for urgent care. PMcardio helps address this issue by supporting healthcare professionals with a reliable AI-driven solution that is available at any time, helping improve decision-making and treatment speed.

With the Breakthrough Device Designation, Powerful Medical will work closely with the FDA to fast-track the model’s review and approval process. The designation is reserved for technologies that offer clear advantages over existing options and meet currently unmet medical needs.

The STEMI AI ECG model—referred to as “Queen of Hearts”—is designed to improve early heart attack detection and triage. It aims to support faster treatment decisions, enhance patient care, and reduce avoidable deaths.